



SDI Review Form 1.6

Journal Name:	<u>Journal of Advances in Medical and Pharmaceutical Sciences</u>
Manuscript Number:	2015_JAMPS_16569
Title of the Manuscript:	COMPARATIVE STUDIES ON THE EFFECTS OF ZIDOVUDINE, NEVIRAPINE, LAMIVUDINE AND BIOCLEAR II ON FEMALE HIV/AIDS CASES IN NIGERIA
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	The manuscript presents weaknesses matter of ethics and scientific rigor in terms of good practice in clinical trial The reference list is poor please complete with rescent references (statements based on outdated references) Authors must precise competing interest relative to BIOCLEAN II product Authors must make a deep revision before a new submission - Ethical issue: Authors should join the ethics committee approval (Why put patients in need of antiretroviral TREATMENT under a treatment not yet validated?) - Authors have to follow WHO Guidelines for good clinical practice (GCP) for trials on pharmaceutical products	No ethical issues not attended to. Corrected No bias at all. Not clear. Trials were recommended for baseline data needed for disclosures for Patenting and Licensing. We are conversant with WHO Guidelines for Good Clinical Practices (GCP) for trials. We are within the ambit of the provisions of the Guidelines.
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		